CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis

Despite advances in therapeutic strategies for multiple sclerosis (MS), the therapy options remain limited with various adverse effects. Here, the therapeutic potential of CKD-506, a novel HDAC6-selective inhibitor, against MS was evaluated in mice with myelin oligodendrocyte glycoprotein(35–55) (MO...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Daekwon, Lee, Ji-Young, Ha, Nina, Park, Jinsol, Baek, Jiyeon, Suh, Donghyeon, Lim, Hee Seon, Ko, Soo Min, Kim, Taehee, Som Jeong, Da, Son, Woo-chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280216/
https://www.ncbi.nlm.nih.gov/pubmed/34262061
http://dx.doi.org/10.1038/s41598-021-93232-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280216/
https://www.ncbi.nlm.nih.gov/pubmed/34262061
http://dx.doi.org/10.1038/s41598-021-93232-6

Ejemplares similares